# US 2004/0082771 A1 · Anti-apoptopic gene SCC-S2 and diagnostic and therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082771 A1
- Document ID: US20040082771A1
- Status: Published application
- Kind: A1
- Application number: 10/627,571
- Filed: 2003-07-25
- Published: 2004-04-29
- Earliest claimed: 2001-01-26
- Assignees: Georgetown University; NeoPharm, Inc.
- Inventors: Usha Kasid; Deepak Kumar; Prafulla Gokhale; Imran Ahmad
- Web page: https://patentgrep.com/patent/US20040082771A1

## CPC

- C07K 14/4747: {Apoptosis related proteins}
- A61K 38/1709: {from mammals}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells.

## Claims

### Claim 1

As isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding amino acids from about 1 to about 188 of the amino acid sequence contained in FIG. 1;
(b) a polynucleotide encoding amino acids from about 2 to about 188 of the amino acid sequence contained in FIG. 1; the polynucleotide complement of the polynucleotide of (a) or (b); and
(c) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).

### Claim 2

An isolated nucleic acid molecule comprising about 10 to about 564 contiguous nucleotides from the coding region identified in FIG. 1.

### Claim 3

An isolated nucleic acid molecule comprising about 50 to about 564 contiguous nucleotides from the coding region of the nucleic acid sequence in FIG. 1.

### Claim 4

An isolated nucleic acid molecule comprising about 100 to about 400 contiguous nucleotides of the coding region of the nucleic acid sequence contained in FIG. 1.

### Claim 5

An isolated nucleic acid molecule comprising about 10 to about 564 contiguous nucleotides from the coding region contained in FIG. 1.

### Claim 6

An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
(a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1; and
(b) amino acids from about 2 to about 188 of the amino acid sequence in FIG. 1.

### Claim 7 (depends on 1)

The isolated nucleic acid molecule of claim 1, which is DNA.

### Claim 8 (depends on 1)

A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.

### Claim 9 (depends on 8)

A recombinant vector produced by the method of claim 8.

### Claim 10 (depends on 9)

A method of making a recombinant host cell comprising introducing the recombinant vector of claim 9 into a host cell.

### Claim 11 (depends on 10)

A recombinant host cell produced by the method of claim 10.

### Claim 12 (depends on 11)

A recombinant method of producing a polypeptide, comprising culturing the recombinant host cell of claim 11 under conditions such that said polypeptide is expressed and recovering said polypeptide.

### Claim 13

An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:
(a) amino acids from about 1 to about 188 of the amino acid sequence contained in FIG. 1; and
(b) amino acids from about 2 to about 188 of the open amino acid sequence contained in FIG. 1.

### Claim 14

An isolated polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
(a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1; and
(b) amino acids from about 2 to about 188 of the amino acid sequence in FIG. 1.

### Claim 15

An isolated polypeptide comprising amino acids selected from the group consisting of:
(a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1; and
(b) amino acids from about 2 to 188 of the amino acid sequence in FIG. 1.

### Claim 16

An epitope-bearing portion of the polypeptide identified in FIG. 1.

### Claim 17 (depends on 16)

The epitope-bearing portion of claim 16, which comprises about 5 to about 30 contiguous amino acids of the protein in FIG. 1.

### Claim 18 (depends on 17)

The epitope-bearing portion of claim 17, which comprises about 10 to about 15 contiguous amino acids of the protein in FIG. 1.

### Claim 19 (depends on 15)

An isolated antibody that binds specifically to the polypeptide of claim 15.

### Claim 20 (depends on 19)

A monoclonal antibody according to claim 19.

### Claim 21

A method of inhibiting apoptosis or proliferation of a cancer cell, comprising inhibiting expression of SCC-S2 in said mammalian cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein said mammalian cell is transformed with a vector encoding an antisense oligonucleotide corresponding tot he SCC-S2 sequence in FIG. 1.

### Claim 23

An antisense oligonucleotide that inhibits the expression of SCC-S2 in a mammalian cell and has a phosphodiester backbone or modified base composition.

### Claim 24 (depends on 23)

The antisense oligonucleotide of claim 23 which is contained in a liposomal formulation.

### Claim 25

A method of treating cancer characterized by SCC-S2 overexpression by administration of an antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule that inhibits SCC-S2 expression.

### Claim 26

A method of treating cancer characterized by SCC-S2 overexpression comprising administering an antibody that specifically binds to SCC-S2.

### Claim 27

A method of treating cancer characterized by SCC-S2 overexpression comprising administration of an antibody that specifically binds to SCC-S2, antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule in combination with radiation, radionucleides, anticancer drugs or other biological agents.

### Claim 28

A method of treating cancer characterized by SCC-S2 overexpression comprising administration of antibody that specifically binds SCC-S2, antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule contained in a liposomal formulation, in combination with radiation, radionucleides, anticancer drugs or other biological agents.

### Claim 29

A method of detecting cancer characterized by SCC-S2 overexpression comprising detecting the levels of SCC-S2 expression and correlating said level of expression to the presence or absence of cancer.

### Claim 30 (depends on 29)

The method of claim 29 which is effected by using a cDNA that hybridizes SCC-S2 and mRNA.

### Claim 31 (depends on 29)

The method of claim 29 which is effected y using an antibody that specifically binds SCC-S2.

### Claim 32

A method for inhibiting cancer cell proliferation and/or metastasis in a cancer patient comprising administering an antibody that specifically binds to SCC-S2, small molecule SCC-S2 inhibitor, or a ribozyme or antisense oligonucleotide that inhibits SCC-S2 expression.

### Claim 33

A method for identifying small molecule inhibitors of the SCC-S2 protein represented by the polypeptide of FIG. 1, wherein the method comprises the steps of:
(a) determining a three dimensional structure of the SCC-S2 protein;
(b) identifying an active site in the structure determined in step (a);
(c) computationally screening a database of compounds to identify molecules that fit in the active site of the protein and selecting the molecules with the highest calculated binding affinity to the protein; and
(d) testing in vitro the SCC-S2 inhibitory activity of the molecules selected in step (c) and identifying one or more SCC-S2 inhibitors.

### Claim 34 (depends on 33)

The method of claim 33, wherein determining the three dimensional structure of the SCC-S2 protein comprises determining the structure through X-ray crystallography.

### Claim 35 (depends on 33)

The method of claim 33, wherein determining the three dimensional structure of the SCC-S2 protein comprises identifying a protein of known structure that is homologous to SCC-S2 and modeling the structure of the SCC-S2 protein based on the structure of the homologous protein.

### Claim 36 (depends on 33)

A method for inhibiting cancer cell proliferation and/or metastasis in a cancer patient comprising administering to the patient a therapeutically effective amount of a compound identified according to claim 33.

### Claim 37

A method for designing small molecule inhibitors of the SCC-S2 protein represented by the polypeptide of FIG. 1, wherein the method comprises the steps of:
(a) determining a three dimensional structure of the SCC-S2 protein;
(b) identifying an active site in the structure determined in step (a);
(c) computationally modeling a compound that is complementary to the active site of the SCC-S2 protein; and
(d) testing in vitro the SCC-S2 inhibitory activity of the molecules selected in step (c) and identifying one or more SCC-S2 inhibitors.

### Claim 38 (depends on 37)

The method of claim 37, wherein determining the three dimensional structure of the SCC-S2 protein comprises determining the structure through X-ray crystallography.

### Claim 39 (depends on 37)

The method of claim 37, wherein determining the three dimensional structure of the SCC-S2 protein comprises identifying a protein of known structure that is homologous to SCC-S2 and modeling the structure of the SCC-S2 protein based on the structure of the homologous protein.

### Claim 40 (depends on 37)

A method for inhibiting cancer cell proliferation and/or metastasis in a cancer patient comprising administering to the patient a therapeutically effective amount of a SCC-S2 inhibitor designed according to claim 37.

### Claim 41 (depends on 33, 36)

The method of claim 36, further comprising obtaining a tumor tissue from the patient and determining the degree of tumor growth and metastasis prior to and after administrating to the patient the SCC-S2 inhibitor identified according to claim 33.

### Claim 42 (depends on 37, 40)

The method of claim 40, further comprising obtaining a tumor tissue from the patient and determining the degree of tumor growth and metastasis prior to and after administering to the patient the SCC-S2 inhibitor designed according to claim 37.
